Gynecomastia Incidence with hCG Treatment
The available evidence does not provide a specific percentage for gynecomastia development in patients treated with human chorionic gonadotropin (hCG), though the FDA drug label does not list gynecomastia as a common adverse effect in the standard prescribing information 1.
What the Evidence Shows
The incidence of gynecomastia with hCG therapy appears to be uncommon and is not well-quantified in the medical literature. The FDA labeling for hCG (PREGNYL®) does not include gynecomastia among its listed adverse reactions or precautions for standard therapeutic use 1.
Context from Clinical Studies
The relationship between hCG and gynecomastia is primarily documented in pathological contexts rather than as a treatment side effect:
Ectopic hCG production: Multiple case reports describe gynecomastia occurring when tumors (lung carcinoma, bladder cancer, choriocarcinoma) secrete hCG ectopically, leading to elevated estradiol levels and subsequent breast tissue enlargement 2, 3, 4, 5, 6
Mechanism: When present, gynecomastia from hCG occurs through stimulation of testicular Leydig cells, which increases testosterone production that is then aromatized to estradiol, creating an elevated estrogen-to-androgen ratio 7, 8
Recent therapeutic data: A 2022 study of 31 men treated with hCG monotherapy for hypogonadal symptoms reported no specific incidence of gynecomastia as an adverse effect 9
Important Clinical Distinctions
Gynecomastia is notably absent from the FDA's precautions for hCG, which instead emphasizes fluid retention, precocious puberty in pediatric patients, and ovarian hyperstimulation in fertility treatments 1. This contrasts sharply with other hormonal therapies where gynecomastia is well-documented—for example, spironolactone causes gynecomastia in 10% at 25 mg/day and up to 52% at doses ≥150 mg/day 10.
Clinical Implications
When gynecomastia does occur in a patient receiving hCG:
- Consider measuring β-hCG, estradiol, testosterone, LH, and FSH levels 7, 11
- Rule out underlying malignancy if β-hCG levels are disproportionately elevated 2, 3, 6
- The gynecomastia typically resolves when the source of excess hCG is removed 2, 5
In summary, while no precise incidence rate exists in the literature, gynecomastia appears to be a rare occurrence with therapeutic hCG use, unlike its well-documented association with ectopic hCG-secreting tumors.